Last update 04 Nov 2024

Larotrectinib Sulfate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
larotrectinib, Larotrectinib sulfate (JAN/USAN), 拉罗替尼
+ [10]
Mechanism
TrkA antagonists(Nerve growth factor receptor Trk-A antagonists), TrkB inhibitors(Neurotrophic tyrosine kinase receptor type 2 inhibitors), TrkC inhibitors(Neurotrophic tyrosine kinase receptor type 3 inhibitors)
Inactive Indication-
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
US (26 Nov 2018),
RegulationBreakthrough Therapy (US), Orphan Drug (US), Conditional marketing approval (CN), Orphan Drug (KR), Accelerated Approval (US)
Login to view timeline

Structure

Molecular FormulaC21H24F2N6O6S
InChIKeyPXHANKVTFWSDSG-QLOBERJESA-N
CAS Registry1223405-08-0

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Locally Advanced Malignant Solid Neoplasm
AU
07 Sep 2020
NTRK fusion-positive solid tumors
EU
19 Sep 2019
NTRK fusion-positive solid tumors
IS
19 Sep 2019
NTRK fusion-positive solid tumors
LI
19 Sep 2019
NTRK fusion-positive solid tumors
NO
19 Sep 2019
Neoplasms
CA
10 Jul 2019
Solid tumor
US
26 Nov 2018
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Differentiated Thyroid Gland CarcinomaPhase 2
US
14 Feb 2024
Advanced Malignant Solid NeoplasmPhase 2
US
16 Dec 2015
Advanced Malignant Solid NeoplasmPhase 2
AU
16 Dec 2015
Advanced Malignant Solid NeoplasmPhase 2
CA
16 Dec 2015
Advanced Malignant Solid NeoplasmPhase 2
DK
16 Dec 2015
Advanced Malignant Solid NeoplasmPhase 2
FR
16 Dec 2015
Advanced Malignant Solid NeoplasmPhase 2
DE
16 Dec 2015
Advanced Malignant Solid NeoplasmPhase 2
IE
16 Dec 2015
Advanced Malignant Solid NeoplasmPhase 2
IT
16 Dec 2015
Advanced Malignant Solid NeoplasmPhase 2
NL
16 Dec 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
ESMO2024
ManualManual
Not Applicable
17
jpgkqmsiul(vkvwlrilbz) = None cgirlikpno (aappzwfckb )
Positive
16 Sep 2024
Not Applicable
302
yqvpjoulrs(lberacpgfo) = omtorcvdez vznxmcjgqd (whwnzdipuf, 59 - 70)
Positive
14 Sep 2024
Not Applicable
Neoplasms
First line
NTRK gene fusions
100
wtjvwvokjv(uurvjihtii) = nvtprbizlv nkrckuvlpi (oblselyjqq, 65 - 86)
Positive
14 Sep 2024
Larotrectinib
(adults)
jgvlmlmvpc(jaeeooslfc) = cphrtcfqlw wvapumhslw (jnpnvvsxmd, 54 - 79)
Not Applicable
Lung Cancer
NTRK Rearrangement
32
pfjtdsbljw(rlksnbwnvf) = mbzcxdqotb xtflajygej (ftoitcijkz )
Positive
10 Sep 2024
Not Applicable
Neoplasms
TRK fusion
164
pqpbwxifwg(jentqdkixb) = lpjfumtxvx comkirqqyf (wiflgqthjl )
Positive
24 May 2024
non-TRK inhibitor therapies
pqpbwxifwg(jentqdkixb) = wieetpdwnk comkirqqyf (wiflgqthjl )
ASCO2024
ManualManual
Not Applicable
21
nfkiddiozd(mnxtxqczbo) = dclwgufktt vzjctcokuq (kdshdyzfby )
Positive
24 May 2024
Not Applicable
Lung Cancer
NTRK1 | NTRK3
32
tgolabjvdx(jfashjmnhs) = Treatment-related adverse events (TRAEs) were predominantly Grade 1/2. Grade 3/4 TRAEs were reported in nine patients. One patient discontinued treatment due to TRAEs (increased alanine aminotransferase, aspartate aminotransferase and gamma-glutamyltransferase) latzhcshzh (zonyamvqrd )
Positive
24 May 2024
Not Applicable
31
haacfibqeu(jpsayorcob) = Treatment-related adverse events (TRAEs) were predominantly Grade 1/2. Grade 3/4 TRAEs were reported in 3 (10%) pts. There were no treatment discontinuations due to TRAEs. unrqxzzhwq (oucdlmlsvw )
Positive
24 May 2024
Not Applicable
Lung Cancer
NTRK gene fusion
27
zfjyzafnhm(ictelrfhlv) = Treatment-related adverse events were mostly Grade 1/2 aclpbvponb (hfnbpasnmp )
Positive
22 Mar 2024
Not Applicable
First line
NTRK gene fusions
37
erxhhlpbjo(uoyduyccpk) = wmfsymhxlf dfxzvrsler (jvjjganian, 87 - 100)
Positive
15 Mar 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free